{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T14:50:53Z","timestamp":1785941453561,"version":"3.56.0"},"reference-count":166,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.eprac.2021.12.010","type":"journal-article","created":{"date-parts":[[2021,12,21]],"date-time":"2021-12-21T20:48:24Z","timestamp":1640119704000},"page":"204-213","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":31,"title":["Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis"],"prefix":"10.1016","volume":"28","author":[{"given":"Zobair M.","family":"Younossi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linda","family":"Henry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib1","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1136\/gutjnl-2019-318813","article-title":"Epidemiology of chronic liver diseases in the USA in the past three decades","volume":"69","author":"Younossi","year":"2020","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.010_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","article-title":"Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention","volume":"15","author":"Younossi","year":"2018","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"7","key":"10.1016\/j.eprac.2021.12.010_bib3","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","article-title":"Nonalcoholic steatohepatitis: Mayo Clinic experiences with a hitherto unnamed disease","volume":"55","author":"Ludwig","year":"1980","journal-title":"Mayo Clin Proc"},{"issue":"12","key":"10.1016\/j.eprac.2021.12.010_bib5","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1002\/hep4.1599","article-title":"The growing burden of disability related to nonalcoholic fatty liver disease: data from the Global Burden of Disease 2007-2017","volume":"4","author":"Paik","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.eprac.2021.12.010_bib6","author":"Paik"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.010_bib7","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1002\/hep.28431","article-title":"Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib8","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.jhep.2019.06.021","article-title":"The global epidemiology of NAFLD and NASH in patients with type 2 diabetes: a systematic review and meta-analysis","volume":"71","author":"Younossi","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.010_bib9","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1016\/S2468-1253(19)30039-1","article-title":"Prevalence, incidence, and outcome of non-alcoholic fatty liver disease in Asia, 1999-2019: a systematic review and meta-analysis","volume":"4","author":"Li","year":"2019","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.010_bib10","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MD.0b013e3182779d49","article-title":"Nonalcoholic fatty liver disease in lean individuals in the United States","volume":"91","author":"Younossi","year":"2012","journal-title":"Medicine (Baltimore)"},{"issue":"8","key":"10.1016\/j.eprac.2021.12.010_bib11","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S2468-1253(20)30077-7","article-title":"Global prevalence, incidence, and outcomes of non-obese or lean non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"5","author":"Ye","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"issue":"8","key":"10.1016\/j.eprac.2021.12.010_bib12","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1002\/hep4.1534","article-title":"Mortality of NAFLD according to the body composition and presence of metabolic abnormalities","volume":"4","author":"Golabi","year":"2020","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.eprac.2021.12.010_bib13","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.jval.2018.04.555","article-title":"Global prevalence of nonalcoholic steatohepatitis (NASH): findings from a targeted literature review","volume":"21","author":"Pedrosa","year":"2018","journal-title":"Value Health"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib14","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1016\/j.cgh.2015.08.010","article-title":"Trends in the burden of nonalcoholic fatty liver disease in a United States cohort of veterans","volume":"14","author":"Kanwal","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib15","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/ajg.2017.5","article-title":"Prevalence of nonalcoholic steatohepatitis-associated cirrhosis in the United States: an analysis of National Health and Nutrition Examination Survey data","volume":"112","author":"Kabbany","year":"2017","journal-title":"Am J Gastroenterol"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib16","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1016\/j.jhep.2018.05.036","article-title":"Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030","volume":"69","author":"Estes","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib17","doi-asserted-by":"crossref","first-page":"211","DOI":"10.4103\/sjg.SJG_122_18","article-title":"Nonalcoholic fatty liver disease burden - Saudi Arabia and United Arab Emirates, 2017-2030","volume":"24","author":"Alswat","year":"2018","journal-title":"Saudi J Gastroenterol"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.010_bib18","doi-asserted-by":"crossref","first-page":"892","DOI":"10.5152\/tjg.2019.19072","article-title":"Growing burden of nonalcoholic fatty liver disease in Turkey: a single-center experience","volume":"30","author":"Y\u0131lmaz","year":"2019","journal-title":"Turk J Gastroenterol"},{"issue":"7","key":"10.1016\/j.eprac.2021.12.010_bib19","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1136\/gut.2009.205088","article-title":"Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years","volume":"59","author":"Wong","year":"2010","journal-title":"Gut"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib20","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1016\/j.jhep.2013.04.027","article-title":"A\u00a0systematic review of follow-up biopsies reveals disease progression in patients with non-alcoholic fatty liver","volume":"59","author":"Pais","year":"2013","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib21","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1016\/j.cgh.2014.04.014","article-title":"Fibrosis progression in nonalcoholic fatty liver vs nonalcoholic steatohepatitis: a systematic review and meta-analysis of paired-biopsy studies","volume":"13","author":"Singh","year":"2015","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.010_bib22","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1016\/j.jhep.2014.11.034","article-title":"Evidence of NAFLD progression from steatosis to fibrosing-steatohepatitis using paired biopsies: implications for prognosis and clinical management","volume":"62","author":"McPherson","year":"2015","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib23","doi-asserted-by":"crossref","first-page":"100305","DOI":"10.1016\/j.jhepr.2021.100305","article-title":"Epidemiology of non-alcoholic fatty liver disease and hepatocellular carcinoma","volume":"3","author":"Younossi","year":"2021","journal-title":"JHEP Rep"},{"issue":"8","key":"10.1016\/j.eprac.2021.12.010_bib24","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.3390\/cells10082034","article-title":"NAFLD-related hepatocarcinoma: the malignant side of metabolic syndrome","volume":"10","author":"Michelotti","year":"2021","journal-title":"Cells"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.010_bib25","doi-asserted-by":"crossref","first-page":"3142","DOI":"10.1007\/s10620-015-3821-7","article-title":"Hepatocellular carcinoma in the setting of non-cirrhotic nonalcoholic fatty liver disease and the metabolic syndrome: US experience","volume":"60","author":"Perumpail","year":"2015","journal-title":"Dig Dis Sci"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.010_bib30","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib26","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.eprac.2021.12.010_bib27","doi-asserted-by":"crossref","first-page":"5023157","DOI":"10.1155\/2020\/5023157","article-title":"The prevalence of NAFLD and fibrosis in bariatric surgery patients and the reliability of noninvasive diagnostic methods","volume":"2020","author":"Soresi","year":"2020","journal-title":"Biomed Res Int"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib28","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0173499","article-title":"Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States","volume":"12","author":"Le","year":"2017","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.010_bib29","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1111\/liv.14828","article-title":"Prevalence of NAFLD, MAFLD and associated advanced fibrosis in the contemporary United States population","volume":"41","author":"Ciardullo","year":"2021","journal-title":"Liver Int"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib31","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1016\/j.cgh.2018.06.011","article-title":"Rates of and factors associated with placebo response in trials of pharmacotherapies for nonalcoholic steatohepatitis: systematic review and meta-analysis","volume":"17","author":"Han","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib32","doi-asserted-by":"crossref","first-page":"1290","DOI":"10.1053\/j.gastro.2020.06.006","article-title":"Bariatric surgery provides long-term resolution of nonalcoholic steatohepatitis and regression of fibrosis","volume":"159","author":"Lassailly","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib33","doi-asserted-by":"crossref","first-page":"238","DOI":"10.1016\/j.jhep.2017.11.012","article-title":"Determinants of fibrosis progression and regression in NASH","volume":"68","author":"Schuppan","year":"2018","journal-title":"J\u00a0Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.010_bib34","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/hep.31173","article-title":"Changes in the Global Burden of Chronic Liver Diseases from 2012 to 2017: the growing impact of NAFLD","volume":"72","author":"Paik","year":"2020","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.eprac.2021.12.010_bib35","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1038\/s41395-018-0088-6","article-title":"NASH leading cause of liver transplant in women: updated analysis of indications for liver transplant and ethnic and gender variances","volume":"113","author":"Noureddin","year":"2018","journal-title":"Am J Gastroenterol"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib36","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cgh.2020.05.064","article-title":"Nonalcoholic steatohepatitis is the most rapidly increasing indication for liver transplantation in the United States","volume":"19","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"37","key":"10.1016\/j.eprac.2021.12.010_bib37","doi-asserted-by":"crossref","first-page":"8294","DOI":"10.3748\/wjg.v22.i37.8294","article-title":"Hepatocellular carcinoma in patients with non-alcoholic fatty liver disease","volume":"22","author":"Wong","year":"2016","journal-title":"World J Gastroenterol"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.010_bib38","doi-asserted-by":"crossref","first-page":"1723","DOI":"10.1002\/hep.28123","article-title":"Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009","volume":"62","author":"Younossi","year":"2015","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib39","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1007\/s12072-015-9679-0","article-title":"Characterization of hepatocellular carcinoma (HCC) in non-alcoholic fatty liver disease (NAFLD) patients without cirrhosis","volume":"10","author":"Mohamad","year":"2016","journal-title":"Hepatol Int"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2021.12.010_bib40","first-page":"644A","article-title":"Insurance status and disease severity are associated with HCC screening adherence","volume":"72","author":"Gergely","year":"2020","journal-title":"Hepatology"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2021.12.010_bib41","first-page":"646A","article-title":"Missed opportunities for hepatocellular carcinoma (HCC) screening and surveillance amongst veterans subsequently diagnosed with HCC","volume":"72","author":"Khan","year":"2020","journal-title":"Hepatology"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2021.12.010_bib42","first-page":"644A","article-title":"Lack of liver disease awareness: Important contributor to late state hepatocellular carcinoma","volume":"72","author":"Rai","year":"2020","journal-title":"Hepatology"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2021.12.010_bib43","first-page":"403A","article-title":"Poor liver disease awareness among adults with NAFLD in the United States","volume":"72","author":"Biswas","year":"2020","journal-title":"Hepatology"},{"issue":"12","key":"10.1016\/j.eprac.2021.12.010_bib44","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1007\/s00535-009-0112-0","article-title":"Hepatocellular carcinoma arising from non-cirrhotic nonalcoholic steatohepatitis","volume":"44","author":"Kawada","year":"2009","journal-title":"J\u00a0Gastroenterol"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib45","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.jhep.2019.04.011","article-title":"European Liver and Intestine Transplant Association (ELITA). Outcomes of liver transplantation for non-alcoholic steatohepatitis: a European Liver Transplant Registry study","volume":"71","author":"Haldar","year":"2019","journal-title":"J\u00a0Hepatol"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.010_bib46","doi-asserted-by":"crossref","first-page":"100192","DOI":"10.1016\/j.jhepr.2020.100192","article-title":"NAFLD and liver transplantation: disease burden, current management and future challenges","volume":"2","author":"Burra","year":"2020","journal-title":"JHEP Rep"},{"issue":"13","key":"10.1016\/j.eprac.2021.12.010_bib47","doi-asserted-by":"crossref","first-page":"2759","DOI":"10.1016\/j.cgh.2019.04.033","article-title":"Increased risk of death in first year after liver transplantation among patients with nonalcoholic steatohepatitis vs liver disease of other etiologies","volume":"17","author":"Nagai","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.010_bib48","doi-asserted-by":"crossref","first-page":"e14","DOI":"10.1097\/TP.0000000000002317","article-title":"Recurrent or de novo allograft steatosis and long-term outcomes after liver transplantation","volume":"103","author":"Narayanan","year":"2019","journal-title":"Transplantation"},{"issue":"9","key":"10.1016\/j.eprac.2021.12.010_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0239393","article-title":"Causes and trends in liver disease and hepatocellular carcinoma among men and women who received liver transplants in the U.S., 2010-2019","volume":"15","author":"Wang","year":"2020","journal-title":"PLoS One"},{"issue":"31","key":"10.1016\/j.eprac.2021.12.010_bib50","doi-asserted-by":"crossref","first-page":"e11518","DOI":"10.1097\/MD.0000000000011518","article-title":"Liver transplantation (LT) for cryptogenic cirrhosis (CC) and nonalcoholic steatohepatitis (NASH) cirrhosis: data from the Scientific Registry of Transplant Recipients (SRTR): 1994 to 2016","volume":"97","author":"Golabi","year":"2018","journal-title":"Medicine (Baltimore)"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.010_bib51","doi-asserted-by":"crossref","first-page":"2915","DOI":"10.1007\/s10620-017-4684-x","article-title":"Liver transplantation for nonalcoholic steatohepatitis in the US: temporal trends and outcomes","volume":"62","author":"Cholankeril","year":"2017","journal-title":"Dig Dis Sci"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib52","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1002\/lt.25003","article-title":"Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: implications for liver transplantation","volume":"24","author":"Younossi","year":"2018","journal-title":"Liver Transpl"},{"key":"10.1016\/j.eprac.2021.12.010_bib53","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1186\/s12876-015-0407-y","article-title":"Risk of de novo post-transplant type 2 diabetes in patients undergoing liver transplant for non-alcoholic steatohepatitis","volume":"15","author":"Stepanova","year":"2015","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.010_bib54","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1097\/TP.0000000000002485","article-title":"Management of recurrent and de novo NAFLD\/NASH after liver transplantation","volume":"103","author":"Germani","year":"2019","journal-title":"Transplantation"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib55","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1097\/TP.0000000000001438","article-title":"Use of everolimus in liver transplantation: recommendations from a working group","volume":"101","author":"De Simone","year":"2017","journal-title":"Transplantation"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib56","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1007\/s12072-020-10038-w","article-title":"Extrahepatic manifestations and healthcare expenditures of non-alcoholic fatty liver disease in the Medicare population","volume":"14","author":"Sayiner","year":"2020","journal-title":"Hepatol Int"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib57","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/0021-9150(94)90025-6","article-title":"Contribution of visceral fat accumulation to the development of coronary artery disease in non-obese men","volume":"107","author":"Nakamura","year":"1994","journal-title":"Atherosclerosis"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib58","doi-asserted-by":"crossref","first-page":"287","DOI":"10.2337\/diacare.19.3.287","article-title":"Insulin resistance and body fat distribution","volume":"19","author":"Yamashita","year":"1996","journal-title":"Diabetes Care"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.010_bib59","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1186\/s12916-019-1321-x","article-title":"Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts","volume":"17","author":"Alexander","year":"2019","journal-title":"BMC Med"},{"issue":"11","key":"10.1016\/j.eprac.2021.12.010_bib60","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1002\/hep4.1419","article-title":"Mortality related to nonalcoholic fatty liver disease is increasing in the United States","volume":"3","author":"Paik","year":"2019","journal-title":"Hepatol Commun"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib61","doi-asserted-by":"crossref","first-page":"101215","DOI":"10.1016\/j.diabet.2020.101215","article-title":"NAFLD, and cardiovascular and cardiac diseases: factors influencing risk, prediction and treatment","volume":"47","author":"Targher","year":"2021","journal-title":"Diabetes Metab"},{"issue":"9","key":"10.1016\/j.eprac.2021.12.010_bib62","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1136\/gutjnl-2020-320622","article-title":"NAFLD and increased risk of cardiovascular disease: clinical associations, pathophysiological mechanisms and pharmacological implications","volume":"69","author":"Targher","year":"2020","journal-title":"Gut"},{"issue":"12","key":"10.1016\/j.eprac.2021.12.010_bib63","doi-asserted-by":"crossref","first-page":"2552","DOI":"10.1016\/j.cgh.2019.02.024","article-title":"Reduced patient-reported outcome scores associate with level of fibrosis in patients with nonalcoholic steatohepatitis","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"11","key":"10.1016\/j.eprac.2021.12.010_bib64","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1002\/hep4.1581","article-title":"Fatigue and pruritus in patients with advanced fibrosis due to nonalcoholic steatohepatitis: the impact on patient-reported outcomes","volume":"4","author":"Younossi","year":"2020","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.010_bib65","doi-asserted-by":"crossref","first-page":"1608","DOI":"10.1053\/j.gastro.2020.12.003","article-title":"The association of histologic and noninvasive tests with adverse clinical and patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"7","key":"10.1016\/j.eprac.2021.12.010_bib66","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1002\/hep4.1710","article-title":"Improvements of fibrosis and disease activity are associated with improvement of patient-reported outcomes in patients with advanced fibrosis due to nonalcoholic steatohepatitis","volume":"5","author":"Younossi","year":"2021","journal-title":"Hepatol Commun"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.010_bib67","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1002\/hep4.1510","article-title":"Nonalcoholic fatty liver disease and alcoholic liver disease are major drivers of liver mortality in the United States","volume":"4","author":"Paik","year":"2020","journal-title":"Hepatol Commun"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.010_bib68","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1002\/hep.28785","article-title":"The economic and clinical burden of nonalcoholic fatty liver disease in the United States and Europe","volume":"64","author":"Younossi","year":"2016","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib69","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1002\/hep.30254","article-title":"Burden of illness and economic model for patients with nonalcoholic steatohepatitis in the United States","volume":"69","author":"Younossi","year":"2019","journal-title":"Hepatology"},{"issue":"9","key":"10.1016\/j.eprac.2021.12.010_bib70","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1111\/hepr.13535","article-title":"Modelling the economic and clinical burden of non-alcoholic steatohepatitis in East Asia: data from Hong Kong","volume":"50","author":"Tampi","year":"2020","journal-title":"Hepatol Res"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib71","doi-asserted-by":"crossref","first-page":"283","DOI":"10.2337\/dc19-1113","article-title":"Economic and clinical burden of nonalcoholic steatohepatitis in patients with type 2 diabetes in the U.S","volume":"43","author":"Younossi","year":"2020","journal-title":"Diabetes Care"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.010_bib72","doi-asserted-by":"crossref","first-page":"815","DOI":"10.1111\/j.1365-2036.2007.03426.x","article-title":"Health-related quality of life in patients with non-alcoholic fatty liver disease","volume":"26","author":"Dan","year":"2007","journal-title":"Aliment Pharmacol Ther"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.010_bib73","doi-asserted-by":"crossref","first-page":"1636","DOI":"10.14309\/ajg.0000000000000375","article-title":"Patients with nonalcoholic steatohepatitis experience severe impairment of health-related quality of life","volume":"114","author":"Younossi","year":"2019","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.010_bib74","doi-asserted-by":"crossref","first-page":"2093","DOI":"10.1016\/j.cgh.2019.01.001","article-title":"Validation of chronic liver disease questionnaire for nonalcoholic steatohepatitis in patients with biopsy-proven nonalcoholic steatohepatitis","volume":"17","author":"Younossi","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.eprac.2021.12.010_bib76","article-title":"Obeticholic acid impact on quality of life in patients with nonalcoholic steatohepatitis: REGENERATE 18-month interim analysis","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.010_bib77","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/s41575-021-00477-7","article-title":"Defining comprehensive models of care for NAFLD","volume":"18","author":"Lazarus","year":"2021","journal-title":"Nat Rev Gastroenterol Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib78","doi-asserted-by":"crossref","first-page":"168","DOI":"10.5009\/gnl19069","article-title":"Extrahepatic manifestations of nonalcoholic fatty liver disease","volume":"14","author":"Li","year":"2020","journal-title":"Gut Liver"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib79","doi-asserted-by":"crossref","first-page":"912","DOI":"10.1053\/j.gastro.2020.11.051","article-title":"AGA clinical practice update on lifestyle modification using diet and exercise to achieve weight loss in the management of nonalcoholic fatty liver disease: expert review","volume":"160","author":"Younossi","year":"2021","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib80","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1053\/j.gastro.2015.04.005","article-title":"Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis","volume":"149","author":"Vilar-Gomez","year":"2015","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib81","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1111\/apt.15580","article-title":"The impact of modifiable risk factors on the long-term outcomes of non-alcoholic fatty liver disease","volume":"51","author":"Paik","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.010_bib82","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1111\/joim.13203","article-title":"Discrepancies between actual weight, weight perception and weight loss intention amongst persons with NAFLD","volume":"289","author":"Nguyen","year":"2021","journal-title":"J\u00a0Intern Med"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib83","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.jhep.2021.05.022","article-title":"Burden of non-alcoholic fatty liver disease in Asia, the Middle East and North Africa: data from Global Burden of Disease 2009-2019","volume":"75","author":"Golabi","year":"2021","journal-title":"J\u00a0Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib84","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.jceh.2019.07.002","article-title":"Natural history of non-alcoholic fatty liver disease: a study with paired liver biopsies","volume":"10","author":"Reddy","year":"2020","journal-title":"J\u00a0Clin Exp Hepatol"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.010_bib85","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1136\/gutjnl-2020-322572","article-title":"Non-alcoholic fatty liver disease and risk of incident diabetes mellitus: an updated meta-analysis of 501 022 adult individuals","volume":"70","author":"Mantovani","year":"2021","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib86","first-page":"508","article-title":"Nonalcoholic steatohepatitis (NASH) - current treatment recommendations and future developments","volume":"57","author":"Roeb","year":"2019","journal-title":"Z\u00a0Gastroenterol"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.010_bib87","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"issue":"21","key":"10.1016\/j.eprac.2021.12.010_bib88","article-title":"Serum biomarkers associated with atherosclerotic cardiovascular disease among patients with non-alcoholic fatty liver disease (NAFLD)","volume":"S1542-3565","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib89","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/apt.15830","article-title":"Clinical assessment for high-risk patients with non-alcoholic fatty liver disease in primary care and diabetology practices","volume":"52","author":"Younossi","year":"2020","journal-title":"Aliment Pharmacol Ther"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2021.12.010_bib90","first-page":"966A","article-title":"Fib-4 and Fibroscan can identify patients with NAFLD who are at risk of liver related events: results of a longitudinal analysis with comparison with liver biopsy","volume":"72","author":"Boursier","year":"2020","journal-title":"Hepatology"},{"issue":"suppl 1","key":"10.1016\/j.eprac.2021.12.010_bib91","first-page":"967A","article-title":"Fibrosis assessed by non-invasive is similar to liver biopsy for predicting clinical outcomes: a Target- NASH study","volume":"72","author":"Barritt","year":"2020","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.010_bib92","doi-asserted-by":"crossref","first-page":"2002","DOI":"10.1007\/s11695-020-04996-1","article-title":"Performance of noninvasive liver fibrosis tests in morbidly obese patients with nonalcoholic fatty liver disease","volume":"31","author":"Alqahtani","year":"2021","journal-title":"Obes Surg"},{"issue":"12","key":"10.1016\/j.eprac.2021.12.010_bib93","doi-asserted-by":"crossref","first-page":"1818","DOI":"10.5858\/2009-0551-OAR1.1","article-title":"Reliability and reproducibility of the Edmondson grading of hepatocellular carcinoma using paired core biopsy and surgical resection specimens","volume":"134","author":"Pirisi","year":"2010","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.010_bib94","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.1053\/j.gastro.2020.01.043","article-title":"Association between fibrosis stage and outcomes of patients with nonalcoholic fatty liver disease: a systematic review and meta-analysis","volume":"158","author":"Taylor","year":"2020","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib95","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"issue":"8","key":"10.1016\/j.eprac.2021.12.010_bib96","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1080\/14656566.2020.1744564","article-title":"Current and new pharmacotherapy options for non-alcoholic steatohepatitis","volume":"21","author":"Sumida","year":"2020","journal-title":"Expert Opin Pharmacother"},{"issue":"8","key":"10.1016\/j.eprac.2021.12.010_bib97","doi-asserted-by":"crossref","first-page":"729","DOI":"10.21037\/atm-20-4354","article-title":"Non-alcoholic fatty liver disease (NAFLD)\/non-alcoholic steatohepatitis (NASH)-related liver fibrosis: mechanisms, treatment and prevention","volume":"9","author":"Tacke","year":"2021","journal-title":"Ann Transl Med"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib98","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1002\/hep.30782","article-title":"Anstee QM; participants of the AASLD\/EASL Workshop. Report on the AASLD\/EASL joint workshop on clinical trial endpoints in NAFLD","volume":"70","author":"Rinella","year":"2019","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib99","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.jhep.2017.11.013","article-title":"Non-invasive assessment of non-alcoholic fatty liver disease: clinical prediction rules and blood-based biomarkers","volume":"68","author":"Vilar-Gomez","year":"2018","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.eprac.2021.12.010_bib100","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-230X-6-33","article-title":"The fatty liver index: a simple and accurate predictor of hepatic steatosis in the general population","volume":"6","author":"Bedogni","year":"2006","journal-title":"BMC Gastroenterol"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.010_bib101","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/apt.13012","article-title":"Fatty liver indices in the multiethnic United States National Health and Nutrition Examination Survey","volume":"41","author":"Ruhl","year":"2015","journal-title":"Aliment Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.eprac.2021.12.010_bib102","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1016\/j.dld.2009.08.002","article-title":"Hepatic steatosis index: a simple screening tool reflecting nonalcoholic fatty liver disease","volume":"42","author":"Lee","year":"2010","journal-title":"Dig Liver Dis"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib104","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1055\/s-0035-1562948","article-title":"Noninvasive evaluation of nonalcoholic fatty liver disease","volume":"35","author":"Castera","year":"2015","journal-title":"Semin Liver Dis"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.010_bib105","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1186\/s12876-019-0961-9","article-title":"Diagnostic accuracy of controlled attenuation parameter (CAP) as a non-invasive test for steatosis in suspected non-alcoholic fatty liver disease: a systematic review and meta-analysis","volume":"19","author":"Pu","year":"2019","journal-title":"BMC Gastroenterol"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib106","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1053\/j.gastro.2017.06.005","article-title":"Agreement between magnetic resonance imaging proton density fat fraction measurements and pathologist-assigned steatosis grades of liver biopsies from adults with nonalcoholic steatohepatitis","volume":"153","author":"Middleton","year":"2017","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib107","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1053\/j.gastro.2016.10.026","article-title":"Magnetic resonance elastography vs transient elastography in detection of fibrosis and noninvasive measurement of steatosis in patients with biopsy-proven nonalcoholic fatty liver disease","volume":"152","author":"Park","year":"2017","journal-title":"Gastroenterology"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.010_bib108","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1002\/hep.21178","article-title":"Development of a simple noninvasive index to predict significant fibrosis in patients with HIV\/HCV coinfection","volume":"43","author":"Sterling","year":"2006","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.010_bib109","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/hep.29721","article-title":"Diagnostic modalities for nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and associated fibrosis","volume":"68","author":"Younossi","year":"2018","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib110","doi-asserted-by":"crossref","first-page":"626","DOI":"10.1053\/j.gastro.2015.11.048","article-title":"Magnetic resonance imaging more accurately classifies steatosis and fibrosis in patients with nonalcoholic fatty liver disease than transient elastography","volume":"150","author":"Imajo","year":"2016","journal-title":"Gastroenterology"},{"issue":"12","key":"10.1016\/j.eprac.2021.12.010_bib112","doi-asserted-by":"crossref","first-page":"694","DOI":"10.12968\/hmed.2018.79.12.694","article-title":"The enhanced liver fibrosis (ELF) test in diagnosis and management of liver fibrosis","volume":"79","author":"Day","year":"2018","journal-title":"Br J Hosp Med (Lond)"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.010_bib113","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1002\/hep.31655","article-title":"Transient versus two-dimensional shear-wave elastography in a multistep strategy to detect advanced fibrosis in NAFLD","volume":"73","author":"Cassinotto","year":"2021","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.010_bib114","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1111\/liv.12584","article-title":"The combination of liver stiffness measurement and NAFLD fibrosis score improves the noninvasive diagnostic accuracy for severe liver fibrosis in patients with nonalcoholic fatty liver disease","volume":"35","author":"Petta","year":"2015","journal-title":"Liver Int"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.010_bib115","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1111\/apt.14219","article-title":"Serial combination of non-invasive tools improves the diagnostic accuracy of severe liver fibrosis in patients with NAFLD","volume":"46","author":"Petta","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.010_bib116","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1053\/j.gastro.2018.12.036","article-title":"Noninvasive assessment of liver disease in patients with nonalcoholic fatty liver disease","volume":"156","author":"Castera","year":"2019","journal-title":"Gastroenterology"},{"issue":"9","key":"10.1016\/j.eprac.2021.12.010_bib117","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2021.23923","article-title":"Performance of the enhanced liver fibrosis test to estimate advanced fibrosis among patients with nonalcoholic fatty liver disease","volume":"4","author":"Younossi","year":"2021","journal-title":"JAMA Netw Open"},{"issue":"11","key":"10.1016\/j.eprac.2021.12.010_bib118","doi-asserted-by":"crossref","first-page":"1833","DOI":"10.1002\/hep4.1765","article-title":"Poor awareness of liver disease among adults with NAFLD in the United States","volume":"5","author":"Alqahtani","year":"2021","journal-title":"Hepatol Commun"},{"key":"10.1016\/j.eprac.2021.12.010_bib119","article-title":"A global survey of physicians knowledge about non-alcoholic fatty liver disease","author":"Younossi","year":"2021","journal-title":"Clin Gastroenterol Hepatol"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.010_bib120","doi-asserted-by":"crossref","first-page":"2100","DOI":"10.1002\/hep.29068","article-title":"Nonalcoholic fatty liver disease in adolescents and young adults: the next frontier in the epidemic","volume":"65","author":"Doycheva","year":"2017","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.010_bib121","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-042843","article-title":"Increasing prevalence of NAFLD\/NASH among children, adolescents and young adults from 1990 to 2017: a population-based observational study","volume":"11","author":"Zhang","year":"2021","journal-title":"BMJ Open"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.010_bib122","doi-asserted-by":"crossref","first-page":"100150","DOI":"10.1016\/j.jhepr.2020.100150","article-title":"Association between remnant lipoprotein cholesterol levels and non-alcoholic fatty liver disease in adolescents","volume":"2","author":"Chin","year":"2020","journal-title":"JHEP Rep"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.010_bib123","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1001\/jama.2012.40","article-title":"Prevalence of obesity and trends in body mass index among US children and adolescents, 1999-2010","volume":"307","author":"Ogden","year":"2012","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib124","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2014-006998","article-title":"Body mass index in school-aged children and the risk of routinely diagnosed non-alcoholic fatty liver disease in adulthood: a prospective study based on the Copenhagen School Health Records Register","volume":"5","author":"Zimmermann","year":"2015","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib125","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1016\/j.jhep.2016.03.019","article-title":"Overweight in late adolescence predicts development of severe liver disease later in life: a 39years follow-up study","volume":"65","author":"Hagstr\u00f6m","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib126","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1016\/j.jhep.2013.09.015","article-title":"Body mass index in childhood and adult risk of primary liver cancer","volume":"60","author":"Berentzen","year":"2014","journal-title":"J\u00a0Hepatol"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib127","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1016\/j.jhep.2016.05.020","article-title":"Childhood predictors of adult fatty liver. The Cardiovascular Risk in Young Finns Study","volume":"65","author":"Suomela","year":"2016","journal-title":"J\u00a0Hepatol"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib128","doi-asserted-by":"crossref","DOI":"10.1001\/jamapediatrics.2019.4498","article-title":"Prevalence of prediabetes among adolescents and young adults in the United States, 2005-2016","volume":"174","author":"Andes","year":"2020","journal-title":"JAMA Pediatr"},{"issue":"21","key":"10.1016\/j.eprac.2021.12.010_bib129","doi-asserted-by":"crossref","first-page":"2292","DOI":"10.1001\/jama.2016.6361","article-title":"Trends in obesity prevalence among children and adolescents in the United States, 1988-1994 through 2013-2014","volume":"315","author":"Ogden","year":"2016","journal-title":"JAMA"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib130","doi-asserted-by":"crossref","first-page":"1386","DOI":"10.1002\/hep.28555","article-title":"The increasing burden of nonalcoholic fatty liver disease among young adults in the United States: a growing epidemic","volume":"64","author":"Mrad","year":"2016","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib131","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.jpeds.2012.08.043","article-title":"Increasing prevalence of nonalcoholic fatty liver disease among United States adolescents, 1988-1994 to 2007-2010","volume":"162","author":"Welsh","year":"2013","journal-title":"J\u00a0Pediatr"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.010_bib132","doi-asserted-by":"crossref","first-page":"e99","DOI":"10.1111\/j.2047-6310.2013.00209.x","article-title":"Non-alcoholic fatty liver disease and hepatocellular carcinoma in a 7-year-old obese boy: coincidence or comorbidity?","volume":"9","author":"Nobili","year":"2014","journal-title":"Pediatr Obes"},{"issue":"11","key":"10.1016\/j.eprac.2021.12.010_bib133","doi-asserted-by":"crossref","first-page":"1761","DOI":"10.5858\/132.11.1761","article-title":"Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis?","volume":"132","author":"Guzman","year":"2008","journal-title":"Arch Pathol Lab Med"},{"issue":"15","key":"10.1016\/j.eprac.2021.12.010_bib134","doi-asserted-by":"crossref","first-page":"1689","DOI":"10.1161\/CIR.0b013e3182a5cfb3","article-title":"Severe obesity in children and adolescents: identification, associated health risks, and treatment approaches: a scientific statement from the American Heart Association","volume":"128","author":"Kelly","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.eprac.2021.12.010_bib135","article-title":"Childhood and adolescent obesity in the United States: a public health concern","volume":"6","author":"Sanyaolu","year":"2019","journal-title":"Glob Pediatr Health"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib136","doi-asserted-by":"crossref","first-page":"1388","DOI":"10.1542\/peds.2006-1212","article-title":"Prevalence of fatty liver in children and adolescents","volume":"118","author":"Schwimmer","year":"2006","journal-title":"Pediatrics"},{"key":"10.1016\/j.eprac.2021.12.010_bib137","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1016\/j.jpeds.2018.11.021","article-title":"Prevalence of nonalcoholic fatty liver disease in children with obesity","volume":"207","author":"Yu","year":"2019","journal-title":"J\u00a0Pediatr"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.010_bib138","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0140908","article-title":"The prevalence of non-alcoholic fatty liver disease in children and adolescents: a systematic review and meta-analysis","volume":"10","author":"Anderson","year":"2015","journal-title":"PLoS One"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.010_bib139","doi-asserted-by":"crossref","first-page":"2068","DOI":"10.14309\/ajg.0000000000001386","article-title":"The changing epidemiology of liver disease among US children and adolescents from 1999 to 2016","volume":"116","author":"Li","year":"2021","journal-title":"Am J Gastroenterol"},{"issue":"10","key":"10.1016\/j.eprac.2021.12.010_bib141","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1002\/hep4.1760","article-title":"Nonalcoholic fatty liver disease prevalence trends among adolescents and young adults in the United States, 2007-2016","volume":"5","author":"Arshad","year":"2021","journal-title":"Hepatol Commun"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib142","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.pcl.2017.01.008","article-title":"Nonalcoholic fatty liver disease in children: hepatic and extrahepatic complications","volume":"64","author":"Selvakumar","year":"2017","journal-title":"Pediatr Clin North Am"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.010_bib143","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1111\/liv.12024","article-title":"Combined paediatric NAFLD fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease","volume":"33","author":"Alkhouri","year":"2013","journal-title":"Liver Int"},{"issue":"7","key":"10.1016\/j.eprac.2021.12.010_bib145","doi-asserted-by":"crossref","first-page":"957","DOI":"10.1002\/lt.24773","article-title":"Hepatic steatosis after pediatric liver transplant","volume":"23","author":"Perito","year":"2017","journal-title":"Liver Transpl"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.010_bib146","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1097\/MPG.0b013e318252a13f","article-title":"Diagnosis of nonalcoholic fatty liver disease in children and adolescents: position paper of the ESPGHAN Hepatology Committee","volume":"54","author":"Vajro","year":"2012","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"7","key":"10.1016\/j.eprac.2021.12.010_bib147","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/sj.ejcn.1602588","article-title":"Predictors of non-alcoholic fatty liver disease in obese children","volume":"61","author":"Sartorio","year":"2007","journal-title":"Eur J Clin Nutr"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib148","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1002\/oby.20173","article-title":"Accuracy of prediction scores and novel biomarkers for predicting nonalcoholic fatty liver disease in obese children","volume":"21","author":"Koot","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"12","key":"10.1016\/j.eprac.2021.12.010_bib149","doi-asserted-by":"crossref","first-page":"E790","DOI":"10.1002\/oby.20523","article-title":"Genetic and clinical markers of elevated liver fat content in overweight and obese Hispanic children","volume":"21","author":"Walker","year":"2013","journal-title":"Obesity (Silver Spring)"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.010_bib150","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1097\/MPG.0b013e31822960be","article-title":"Biochemical parameters and anthropometry predict NAFLD in obese children","volume":"53","author":"Maffeis","year":"2011","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"11","key":"10.1016\/j.eprac.2021.12.010_bib151","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1016\/j.ejrad.2012.06.020","article-title":"Ultrasonography as a non-invasive tool for detection of nonalcoholic fatty liver disease in overweight\/obese Egyptian children","volume":"81","author":"El-Koofy","year":"2012","journal-title":"Eur J Radiol"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.010_bib153","doi-asserted-by":"crossref","DOI":"10.1136\/bmjgast-2021-000780","article-title":"Prevalence of and risk factors for non-alcoholic fatty liver disease (NAFLD) and fibrosis among young adults in Egypt","volume":"8","author":"Tomah","year":"2021","journal-title":"BMJ Open Gastroenterol"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib154","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1002\/cld.1027","article-title":"Epidemiology of pediatric nonalcoholic fatty liver disease","volume":"17","author":"Yu","year":"2021","journal-title":"Clin Liver Dis (Hoboken)"},{"issue":"14","key":"10.1016\/j.eprac.2021.12.010_bib156","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1001\/jama.2018.0158","article-title":"US Burden of Disease Collaborators. The state of US health, 1990-2016: burden of diseases, injuries, and risk factors among US states","volume":"319","author":"Mokdad","year":"2018","journal-title":"JAMA"},{"issue":"8","key":"10.1016\/j.eprac.2021.12.010_bib157","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1016\/j.metabol.2016.01.008","article-title":"Similarities and differences between pediatric and adult nonalcoholic fatty liver disease","volume":"65","author":"Crespo","year":"2016","journal-title":"Metabolism"},{"issue":"7","key":"10.1016\/j.eprac.2021.12.010_bib158","doi-asserted-by":"crossref","first-page":"1967","DOI":"10.1053\/j.gastro.2020.01.048","article-title":"Nonalcoholic fatty liver disease in children: unique considerations and challenges","volume":"158","author":"Goldner","year":"2020","journal-title":"Gastroenterology"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib159","doi-asserted-by":"crossref","first-page":"1113","DOI":"10.1002\/hep.23133","article-title":"Nonalcoholic steatohepatitis in children: a multicenter clinicopathological study","volume":"50","author":"Carter-Kent","year":"2009","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.010_bib160","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1111\/obr.12271","article-title":"Paediatric non-alcoholic fatty liver disease: an overview","volume":"16","author":"AlKhater","year":"2015","journal-title":"Obes Rev"},{"issue":"2","key":"10.1016\/j.eprac.2021.12.010_bib161","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1097\/MPG.0000000000001482","volume":"64","author":"Vos","year":"2017","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.010_bib163","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1007\/s00431-019-03362-3","article-title":"Comparison of diagnostic accuracy of screening tests ALT and ultrasound for pediatric non-alcoholic fatty liver disease","volume":"178","author":"Draijer","year":"2019","journal-title":"Eur J Pediatr"},{"issue":"11","key":"10.1016\/j.eprac.2021.12.010_bib164","doi-asserted-by":"crossref","first-page":"2606","DOI":"10.1111\/liv.14658","article-title":"Normal liver stiffness and influencing factors in healthy children: an individual participant data meta-analysis","volume":"40","author":"Li","year":"2020","journal-title":"Liver Int"},{"issue":"5","key":"10.1016\/j.eprac.2021.12.010_bib165","doi-asserted-by":"crossref","first-page":"1161","DOI":"10.1111\/liv.14748","article-title":"Non-invasive diagnosis methods are needed in paediatric non-alcoholic fatty liver disease","volume":"41","author":"Li","year":"2021","journal-title":"Liver Int"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib166","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1001\/jama.2018.20579","article-title":"Effect of a low free sugar diet vs usual diet on nonalcoholic fatty liver disease in adolescent boys: a randomized clinical trial","volume":"321","author":"Schwimmer","year":"2019","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.eprac.2021.12.010_bib167","doi-asserted-by":"crossref","DOI":"10.1111\/ijpo.12630","article-title":"Effects of a carbohydrate-restricted diet on hepatic lipid content in adolescents with non-alcoholic fatty liver disease: a pilot, randomized trial","volume":"15","author":"Goss","year":"2020","journal-title":"Pediatr Obes"},{"key":"10.1016\/j.eprac.2021.12.010_bib168","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/j.cct.2018.03.014","article-title":"Effectiveness of a carbohydrate restricted diet to treat non-alcoholic fatty liver disease in adolescents with obesity: trial design and methodology","volume":"68","author":"Dowla","year":"2018","journal-title":"Contemp Clin Trials"},{"issue":"4","key":"10.1016\/j.eprac.2021.12.010_bib169","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1016\/j.pcad.2014.09.010","article-title":"Supporting public health priorities: recommendations for physical education and physical activity promotion in schools","volume":"57","author":"Hills","year":"2015","journal-title":"Prog Cardiovasc Dis"},{"issue":"16","key":"10.1016\/j.eprac.2021.12.010_bib170","doi-asserted-by":"crossref","first-page":"1659","DOI":"10.1001\/jama.2011.520","article-title":"Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial","volume":"305","author":"Lavine","year":"2011","journal-title":"JAMA"},{"issue":"6","key":"10.1016\/j.eprac.2021.12.010_bib171","doi-asserted-by":"crossref","first-page":"1141","DOI":"10.1053\/j.gastro.2016.08.027","article-title":"In children with nonalcoholic fatty liver disease, cysteamine bitartrate delayed release improves liver enzymes but does not reduce disease activity scores","volume":"151","author":"Schwimmer","year":"2016","journal-title":"Gastroenterology"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib172","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1002\/hep.31317","article-title":"Alanine aminotransferase and gamma-glutamyl transpeptidase predict histologic improvement in pediatric nonalcoholic steatohepatitis","volume":"73","author":"Newton","year":"2021","journal-title":"Hepatology"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.010_bib173","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1097\/MPG.0b013e318290d138","article-title":"A\u00a0multidisciplinary clinical program is effective in stabilizing BMI and reducing transaminase levels in pediatric patients with NAFLD","volume":"57","author":"DeVore","year":"2013","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"},{"issue":"3","key":"10.1016\/j.eprac.2021.12.010_bib174","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1111\/j.1365-2036.2009.04181.x","article-title":"Symptoms and quality of life in obese children and adolescents with non-alcoholic fatty liver disease","volume":"31","author":"Kistler","year":"2010","journal-title":"Aliment Pharmacol Ther"},{"issue":"1","key":"10.1016\/j.eprac.2021.12.010_bib175","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/MPG.0b013e31826f2b8c","article-title":"Psychosocial outcomes for children with nonalcoholic fatty liver disease over time and compared with obese controls","volume":"56","author":"Kerkar","year":"2013","journal-title":"J\u00a0Pediatr Gastroenterol Nutr"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X21014178?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X21014178?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T22:12:17Z","timestamp":1761516737000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X21014178"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":166,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2022,2]]}},"alternative-id":["S1530891X21014178"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2021.12.010","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Fatty Liver Through the Ages: Nonalcoholic Steatohepatitis","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2021.12.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 AACE. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}